Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...
Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
